Arulananda, Surein
O’Brien, Megan
Evangelista, Marco
Jenkins, Laura J.
Poh, Ashleigh R. http://orcid.org/0000-0001-8375-4753
Walkiewicz, Marzena
Leong, Trishe
Mariadason, John M. http://orcid.org/0000-0001-9123-7684
Cebon, Jonathan
Balachander, Srividya B.
Cidado, Justin R.
Lee, Erinna F.
John, Thomas
Fairlie, Walter D. http://orcid.org/0000-0002-2498-1160
Article History
Received: 20 January 2021
Revised: 15 April 2021
Accepted: 1 May 2021
First Online: 28 May 2021
Conflict of interest
: Assoc. Prof. W. Douglas Fairlie and Dr Erinna Lee were previously employees of The Walter and Eliza Hall Institute where they were involved in collaborations with AbbVie and Genentech to develop and characterize BH3-mimetic drugs and receive payments in respect of Venetoclax. AstraZeneca provided Fairlie and Lee’s laboratory with AZD0466, AZD4320 and AZD5991 to conduct these studies, however, they did not receive any financial support. Dr Surein Arulananda has received speaker fees and travel support from Merck-Sharpe Dohme, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb and Roche, outside the submitted work. Assoc. Prof. Thomas John has received speaker fees and travel support from Pfizer, AstraZeneca, BMS, Novartis, Merck Sharp & Dohme, Boehringer-Ingelheim, Takeda, Merck and Roche, outside the submitted work. Dr Jonathan Cebon has received speaker fees and travel support from Amgen, Bristol-Myers Squibb, GlaxoSmith Kline, Merck; Merck Sharp & Dohme and Novartis, outside the submitted work. Dr Justin Cidado and Dr Srividya Balachander are current or former AstraZeneca employees and shareholders.